For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Anergen, Inc.

USPTO Granted Patents = 17

Forward Citations = 392

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Brian R Clark (9 out of 21 patents)

Somesh D Sharma (9 out of 21 patents)

Bishwajit Nag (8 out of 40 patents)

4. L Bernard Lerch (4 out of 6 patents)

5. Bernard L Lerch (2 out of 3 patents)

6. Michael A McCutcheon (2 out of 2 patents)

7. Nancy G Wehner (2 out of 2 patents)

8. Edward G Spack (2 out of 2 patents)

9. Wayne R Kindsvogel (1 out of 104 patents)

10. Jane A Gross (1 out of 52 patents)

11. Subramaniam Sriram (1 out of 8 patents)

12. Eva Pia Reich (1 out of 1 patent)

13. Harden M McConnell (1 out of 15 patents)

14. Prabha V Mukku (1 out of 1 patent)

15. Teresa Kendrick (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 6451314 - MHC conjugates useful in ameliorating autoimmunity (2002-09-17),

2. 6218132 - Method for monitoring T cell reactivity (2001-04-17),

3. 6106840 - MHC conjugates useful in ameliorating autoimmunity (2000-08-22),

4. 6060309 - Immune mediators and related methods (2000-05-09),

5. 6045796 - Vaccination with peptide of MHC class II molecules for treatment of (2000-04-04),

6. 6007820 - Purification and characterization of MHC-peptide complexes useful in (1999-12-28),

7. 5824315 - Binding affinity of antigenic peptides for MHC molecules (1998-10-20),

8. 5763585 - Method of making MHC-peptide complexes using metal chelate affinity (1998-06-09),

9. 5750356 - Method for monitoring T cell reactivity (1998-05-12),

10. 5734023 - MHC class II .beta. chain/peptide complexes useful in ameliorating (1998-03-31),

11. 5595881 - Method for the detection of antigen presenting cells (1997-01-21),

12. 5334391 - Intracellularly cleavable compounds (1994-08-02),

13. 5284935 - MHC-mediated toxic conjugates useful in ameliorating autoimmunity (1994-02-08),

14. 5260422 - MHC conjugates useful in ameliorating autoimmunity (1993-11-09),

15. 5194425 - MHC-mediated toxic conjugates useful in ameliorating autoimmunity (1993-03-16),

Anergen, Inc. is a biotechnology company specializing in the development of novel immunotherapies for autoimmune diseases. Our cutting-edge research focuses on harnessing the power of the immune system to restore tolerance and treat conditions such as multiple sclerosis and rheumatoid arthritis. With a dedicated team of scientists and a commitment to innovation, we aim to improve the lives of patients by providing safe and effective treatment options.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

17 Patents

#105 in Seattle, WA

#376 in Washington

#18,300 in US

#34,819 in the World

Seattle, WA, United States of America

Anergen, Inc.

Forward Citations = 392

15 inventors:

Brian R Clark (9 out of 21 patents)

Somesh D Sharma (9 out of 21 patents)

Bishwajit Nag (8 out of 40 patents)

4. L Bernard Lerch (4 out of 6 patents)

5. Bernard L Lerch (2 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…